To investigate the efficacy and safety of total oral regimen containing
ixazomib in multidrug-resistant relapsed and refractory
multiple myeloma(RRMM). A total of 38 patients were retrospectively analyzed from August 2018 to January 2020 in the First Affiliated Hospital of Soochow University. The overall response rate (ORR)was 36.8%. Among them, the very good partial response (VGPR) or better rate was 23.7%, and the complete response (CR) rate was 5.3%. The ORR was 41.7% in patients receiving
ixazomib-
lenalidomide-
dexamethasone (IRD) regimen. Median PFS was 5 months and median OS was 7.5 months. The ORR was 50% after second-line
therapy, 40% after third-line
therapy and 12.5% after forth-line
therapy or more. The ORR was 29.0% in
bortezomib-refractory patients, 38.0% in
lenalidomide-refractory patients, 21.4% in bortezmoib &
lenalidomide dual refractory patients. Grade 3-4 hematological adverse events (AEs) were reported in 21% patients. Common hematological AEs included
lymphopenia,
neutropenia,
thrombocytopenia. Other usual AEs were
fatigue and
diarrhea. No grade 3-4
peripheral neuropathy was recorded. In the treatment of relapsed/refractory
multiple myeloma patients with multidrug resistance, the total oral regimens containing
ixazomib demonstrate reliable efficacy and safety. Early administration of
ixazomib at first or second relapse is suggested for more favorable clinical outcome.